It refers to the process whereby red blood cells rupture and their contents leak out into the bloodstream. Hemolysis can happen in vivo or in vitro, the first being linked to medical conditions, and the latter being a marked challenge for the medical sector as it hinders clinical testing.
Below we discuss the two scenarios of red blood cell lysis, when it occurs in the body and outside of it, giving an overview of how it occurs and its significance.
Red blood cell lysis in vivo
In vivo hemolysis has numerous causes and is linked with multiple diseases. It is characteristic of a group of conditions known as hemolytic anemias, the causes of which include immune-mediated erythrocyte destruction, such as neonatal isoerythrolysis; incompatible blood transfusion; drugs including penicillin and heparin; fragmentation, such as disseminated intravascular coagulation (DIC), vasculitis, and uremia; hemoparasites, such as Babesia spp.; infectious agents, including Leptospira, Ehrlichia, Clostridium, and equine infectious anemia virus; hypo-osmolality; hypophosphatemia; some chemicals and plants, such as red maple and phenothiazine; and liver failure.
Other causes of hemolysis include artificial heart values, heart-lung bypass machines, pyruvate kinase deficiency, Wiscott-Aldridge Syndrome, HELLP Syndrome, and more. In total, there may be more than 50 causes of in vivo hemolysis. These causes can be classified as immune or nonimmune, hereditary or acquired.
Essentially, hemolysis occurs in vivo when the rate of red blood cell destruction is increased. This leads to hemoglobin being released into the bloodstream. Usually, red blood cells live for around 120 days, and when they die, the spleen removes them from the blood.
Uterine Artery Hemorrhage
Hemorrhage from the uterine arteries (i.e., the uterine branch of the vaginal artery), the uterine artery, and the uterine branch of the ovarian artery is the most common cause of death of the postpartum mare. A study of 98 mares that died postpartum revealed that 40 died from a ruptured uterine artery.61 It is uncommon for these arteries to rupture at times other than in the first several days postpartum.
The condition is usually seen in older mares. Affected mares are often initially in quite an amount of pain, especially if the blood is contained within the broad ligament. The rectal examination in these mares generally reveals a fluctuant mass in the broad ligament. If the broad ligament ruptures and the blood gains access to the abdominal cavity, the mare may not exhibit as much pain. On rectal examination, the broad ligament has a more edematous feel. These mares generally have very pale mucous membranes, a weak pulse, and an elevated heart rate, and they are anxious and often sweating.
Treatment varies depending on the clinician, but it essentially follows the approach taken for hemorrhagic shock (Gentaur).58 Attempts to ligate the ruptured artery have met with limited success.
MULTIPLEX KIT PCR MASTITIS PCR kit | |
PCR-MPX218-48D | Bioingentech |
MULTIPLEX KIT PCR MASTITIS PCR kit | |
PCR-MPX218-96D | Bioingentech |
MULTIPLEX KIT PCR Babesia & Theileria PCR kit | |
PCR-MPX401-48D | Bioingentech |
MULTIPLEX KIT PCR Babesia & Theileria PCR kit | |
PCR-MPX401-96D | Bioingentech |
Leaf PCR Kit | |
11140007-1 | Glycomatrix |
Filter Transfer Sets
Configurable filter assemblies consist of filter capsules assembled with tubing and connectors for immediate connection to single-use or stainless-steel systems.
Filter Transfer Sets offer:
- Particle, pre- and bioburden reduction filters
- Sterile and mycoplasma retention filters
- Standardized configurations for rapid implementation
- Broad choice of components, filters, tubes and connectors
- Closed system available
Filter Assemblies | Virus Filter Assemblies | Filter Assemblies Final Filling | Sensor Assemblies | Large Scale Filter Assemblies | |
---|---|---|---|---|---|
Product Name | Filter Transfer Sets | Virus Filter Transfer Sets | Filter Transfer Sets Final Filling | Sensor Transfer Sets | Maxicaps® MR |
Scale | PD – Commercial Manufacturing | PD – Commercial Manufacturing | Clinical – Commercial Manufacturing | PD – Commercial Manufacturing | Commercial Manufacturing |
Filtration Area | 0.016 – 3 m2 0.17 – 32.3 ft2 |
0.2 – 2.4 m2 2.15 – 28.8 ft2 |
0.05 – 1 m2 0.5 – 10.8 ft2 |
N/A | 3 – 27 m2 32.3 – 290.6 ft2 |
Delivery Condition | Sterile | Sterile | Sterile | Sterile | Non-sterile | Sanitary | Sterile |
Sterilization Method | Gamma irradiation | Autoclave | Gamma irradiation | Gamma irradiation | Gamma irradiation | None | Gamma irradiation / Autoclave |
Avoiding hemolysis of biological samples
Hemolysis of blood samples before they are tested is a major challenge within the medical industry. It is particularly impactful on emergency departments who need to acquire accurate test results with speed. Hemolysis that occurs in vitro can happen during the collection of the sample, or through the handling of the sample.
It is a significant problem for clinical testing because the lysis of red blood cells can affect the results. The contents that leak from the broken-down cells can directly impact the reading of the results, or they can cause interferences with laboratory analyzers.
Rat Cholesterol ELISA ELISA | |
E01A11128 | BlueGene |
Goat Cholesterol ELISA ELISA | |
E01A46041 | BlueGene |
Mouse Cholesterol ELISA ELISA | |
E01A19869 | BlueGene |
Human Cholesterol ELISA ELISA | |
E01A2368 | BlueGene |
Sheep Cholesterol ELISA ELISA | |
E01A98335 | BlueGene |
The magnitude of the impact is dependent on the type of test being performed and the reagents being used. Tests for potassium, lactate dehydrogenase, and aspartate aminotransferase are particularly affected by hemolysis, where the release of cellular contents into the blood plasma falsely increases the values of the target substances.
Other tests are affected in different ways. When only small levels of hemolysis are detected, the levels are reported along with the test result. When levels of hemolysis are high, the results cannot be relied on, and it calls for a recollection of the sample.
Studies have found that hemolysis is the most common cause for samples to be rejected, with 60% of rejections being attributed to hemolysis. Hemolyzed specimens are five times more frequent than the second most common cause of specimen rejection. This demonstrates the severity of the problem that hemolysis brings to the medical community.
Uterine hemorrhage
Hemorrhage from the uterine artery is most commonly seen in older multiparous mares, but has been seen in primiparous mares. Dystocia (q.v.) does not appear to increase its incidence. Hemorrhage is not always fatal if it is contained within the broad ligament and associated tissues, but the mare will exsanguinate if the hematoma ruptures into the peritoneal cavity or the uterus.
Initial signs, seen within minutes or hours of parturition, are acute moderate to severe colic and sweating, with rapid pulse, which progresses to cardiovascular shock. The mare should be kept quiet with mild sedatives and analgesics. Hypotensive tranquilizers such as acepromazine or detomidine may help to encourage clotting to occur in some cases but may risk acceler-ating cardiovascular collapse (q.v.) in others. Fluid therapy with blood or plasma expander or hypertonic saline does not seem to alter the course of the condition and may be contraindicated as it often stresses the mare and increases blood pressure and further hemorrhage, delaying clotting. Treatment with hypertonic saline solutions has been reported to be useful in some cases. In mares that survive, the hematoma will be palpable for some considerable time.
Horse Horse; Equine herpes virus ELISA Kit |
|||
MBS1610084-10x96StripWells | MyBiosource | 10x96-Strip-Wells | 4470 EUR |
Horse Horse; Equine herpes virus ELISA Kit |
|||
MBS1610084-5x96StripWells | MyBiosource | 5x96-Strip-Wells | 2270 EUR |
Horse Horse; Equine herpes virus ELISA Kit |
|||
MBS1610084-96StripWells | MyBiosource | 96-Strip-Wells | 540 EUR |
Horse IgG |
|||
31C-CH0801 | Fitzgerald | 50 mg | Ask for price |
Horse IgM |
|||
31C-CH0813 | Fitzgerald | 1 mg | 369 EUR |
Horse IgG |
|||
E61I024 | EnoGene | 1mg | 225 EUR |
Horse CRP |
|||
8108 | Life Diagnostics | 0.1 mg | 320 EUR |
Horse IgG |
|||
IHR-8160-10 | ImmunoBioscience | 10 mg | 47.75 EUR |
Horse IgG |
|||
IHR-8160-100 | ImmunoBioscience | 100 mg | 88.2 EUR |
Horse IgG |
|||
MBS8574979-1mg | MyBiosource | 1mg | 305 EUR |
Horse IgG |
|||
MBS8574979-5x1mg | MyBiosource | 5x1mg | 1220 EUR |
Horse IgM |
|||
MBS537237-1mg | MyBiosource | 1mg | 645 EUR |
Horse IgM |
|||
MBS537237-5x1mg | MyBiosource | 5x1mg | 2755 EUR |
Horse IgG |
|||
MBS537629-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Horse GGTP |
|||
QY-E120082 | Qayee Biotechnology | 96T | 573.6 EUR |
Horse milk |
|||
MBS571955-05mL | MyBiosource | 0.5mL | 195 EUR |
Horse milk |
|||
MBS571955-5x05mL | MyBiosource | 5x0.5mL | 735 EUR |
Horse Serum |
|||
abx098260-100ml | Abbexa | 100 ml | 410.4 EUR |
Horse serum |
|||
IHR-8139 | ImmunoBioscience | 20 ml | 47.75 EUR |
Horse serum |
|||
abx810187-10nmol | Abbexa | 10 nmol | 287.5 EUR |
Horse serum |
|||
abx810187-5nmol | Abbexa | 5 nmol | 250 EUR |
Horse Serum |
|||
MBS571961-1mL | MyBiosource | 1mL | 160 EUR |
Horse Serum |
|||
MBS571961-5x1mL | MyBiosource | 5x1mL | 575 EUR |
Horse leptin |
|||
MBS400029-01mg | MyBiosource | 0.1mg | 220 EUR |
Horse leptin |
|||
MBS400029-05mg | MyBiosource | 0.5mg | 545 EUR |
Horse leptin |
|||
MBS400029-10mg | MyBiosource | 10mg | 4765 EUR |
Horse leptin |
|||
MBS400029-1mg | MyBiosource | 1mg | 845 EUR |
Horse leptin |
|||
MBS400029-5mg | MyBiosource | 5mg | 3080 EUR |
Horse Blocker |
|||
20960002-1 | Glycomatrix | 100 mL | 53.99 EUR |
Horse Blocker |
|||
20960002-2 | Glycomatrix | 200 mL | 78.08 EUR |
Horse Glucose |
|||
QY-E120080 | Qayee Biotechnology | 96T | 573.6 EUR |
Horse Lactate |
|||
QY-E120087 | Qayee Biotechnology | 96T | 573.6 EUR |
Horse Haptoglobin |
|||
8150 | Life Diagnostics | 1 mg | 275 EUR |
Horse IgG (Fc) |
|||
31C-CH0804 | Fitzgerald | 1 mg | 304 EUR |
Horse IgG (Fc) |
|||
MBS537860-1mg | MyBiosource | 1mg | 540 EUR |
Horse IgG (Fc) |
|||
MBS537860-5x1mg | MyBiosource | 5x1mg | 2280 EUR |
Horse IgG (HRP) |
|||
65C-CH0803 | Fitzgerald | 1 mg | 169 EUR |
Horse IgG (Fab) |
|||
31C-CH0810 | Fitzgerald | 2 mg | 342 EUR |
Horse IgG (Fab) |
|||
MBS537569-2mg | MyBiosource | 2mg | 595 EUR |
Horse IgG (Fab) |
|||
MBS537569-5x2mg | MyBiosource | 5x2mg | 2515 EUR |
Horse IgG (HRP) |
|||
MBS538961-1mg | MyBiosource | 1mg | 325 EUR |
Horse IgG (HRP) |
|||
MBS538961-5x1mg | MyBiosource | 5x1mg | 1320 EUR |
Horse IgG (FITC) |
|||
65C-CH0802 | Fitzgerald | 1 mg | 148 EUR |
Horse IgG (FITC) |
|||
MBS538960-1mg | MyBiosource | 1mg | 305 EUR |
Horse IgG (FITC) |
|||
MBS538960-5x1mg | MyBiosource | 5x1mg | 1230 EUR |
Horse CRP ELISA |
|||
KT-487 | Kamiya Biomedical Company | 96 tests | 524 EUR |
Horse IgA ELISA |
|||
KT-609 | Kamiya Biomedical Company | 96 tests | 524 EUR |
Horse IgG ELISA |
|||
KT-610 | Kamiya Biomedical Company | 96 tests | 524 EUR |
Horse IgM ELISA |
|||
KT-611 | Kamiya Biomedical Company | 96 tests | 524 EUR |
Horse SAA ELISA |
|||
KT-660 | Kamiya Biomedical Company | 96 tests | 573 EUR |
Horse Serum - 100ml |
|||
HO-290/100 | Biosera France - Medical Scientific Equipment | 100ml | 10.29 EUR |
Horse Serum - 500ml |
|||
HO-290/500 | Biosera France - Medical Scientific Equipment | 500ml | 37.9 EUR |
Horse Ig fraction |
|||
31R-1005 | Fitzgerald | 10 mg | 136.8 EUR |
Horse Ig fraction |
|||
31R-1029 | Fitzgerald | 10 mg | 92 EUR |
Horse IgG protein |
|||
31R-1055 | Fitzgerald | 10 mg | 153 EUR |
Doner Horse Serum |
|||
F0605-050 | GenDepot | 500ml | 181.2 EUR |
Horse Genomic DNA |
|||
PCR-706 | Jena Bioscience GmbH | 20µg | 90.1 EUR |
Donor Horse Serum |
|||
SER006 | Neuromics | each | 46.8 EUR |
Horse Ig fraction |
|||
AS10-866 | Agrisera AB | 10 mg | 113 EUR |
Horse Ig Fraction |
|||
MBS687004-10mg | MyBiosource | 10mg | 135 EUR |
Horse Ig Fraction |
|||
MBS687004-5x10mg | MyBiosource | 5x10mg | 455 EUR |
Donor Horse Serum |
|||
MBS556472-3L | MyBiosource | 3L | 380 EUR |
Donor Horse Serum |
|||
MBS556472-5x3L | MyBiosource | 5x3L | 1555 EUR |
Horse Ig fraction |
|||
MBS5308129-10mg | MyBiosource | 10mg | 200 EUR |
Horse Ig fraction |
|||
MBS5308129-5x10mg | MyBiosource | 5x10mg | 750 EUR |
Normal Horse Serum |
|||
88-NE21 | Fitzgerald | 100 ml | Ask for price |
Normal Horse Serum |
|||
88R-1020 | Fitzgerald | 10 ml | 166 EUR |
Horse RBC antibody |
|||
20R-RR023 | Fitzgerald | 20 mg | 389 EUR |
Horse RBC antibody |
|||
20R-RR024 | Fitzgerald | 5 mg | 676 EUR |
Horse IgA Antibody |
|||
GWB-Q00116 | GenWay Biotech | 2 ml | Ask for price |
Horse CD4 Antibody |
|||
GWB-Q00961 | GenWay Biotech | 2 ml | Ask for price |
Horse CD2 Antibody |
|||
GWB-Q01398 | GenWay Biotech | 2 ml | Ask for price |
Horse IgM Antibody |
|||
GWB-9864FA | GenWay Biotech | 1 mg | Ask for price |
Horse IgA Antibody |
|||
GWB-AD0357 | GenWay Biotech | 1 mg | Ask for price |
Horse thyroxine(T4) |
|||
QY-E120089 | Qayee Biotechnology | 96T | 573.6 EUR |
Horse Cortisol(COR) |
|||
QY-E120091 | Qayee Biotechnology | 96T | 573.6 EUR |
Horse Estrogen-E- |
|||
QY-E120100 | Qayee Biotechnology | 96T | 580 EUR |
Source :